Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 514.5
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 274.3
熱評(píng):
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 867.5
括阿斯利康、諾華、輝瑞、武田等4家外資藥企的6個(gè)產(chǎn)品;國產(chǎn)藥物則包括施慧達(dá)藥業(yè)的苯磺酸左氨氯地平片、上海現(xiàn)代制藥(600420.SH,股票簡(jiǎn)稱“國藥現(xiàn)代”)的硝苯地平控釋片、石藥歐意的馬來酸左氨氯地平
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 604.2
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 330
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 136.1
植物、真菌或細(xì)菌。對(duì)于現(xiàn)代制藥行業(yè)而言,生物多樣性對(duì)于新藥篩選和開發(fā)至關(guān)重要,約70% 的癌癥藥物都來源于自然。美國150 種最常用藥物中,有約 118 種(如抗抑郁藥、抗生素和抗血小板藥物等)來自于
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 799.7
圖片
視頻
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 274.3
熱評(píng):
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 867.5
熱評(píng):
括阿斯利康、諾華、輝瑞、武田等4家外資藥企的6個(gè)產(chǎn)品;國產(chǎn)藥物則包括施慧達(dá)藥業(yè)的苯磺酸左氨氯地平片、上海現(xiàn)代制藥(600420.SH,股票簡(jiǎn)稱“國藥現(xiàn)代”)的硝苯地平控釋片、石藥歐意的馬來酸左氨氯地平
熱評(píng):
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 604.2
熱評(píng):
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 330
熱評(píng):
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 136.1
熱評(píng):
植物、真菌或細(xì)菌。對(duì)于現(xiàn)代制藥行業(yè)而言,生物多樣性對(duì)于新藥篩選和開發(fā)至關(guān)重要,約70% 的癌癥藥物都來源于自然。美國150 種最常用藥物中,有約 118 種(如抗抑郁藥、抗生素和抗血小板藥物等)來自于
熱評(píng):
Shanghai Shyndec Pharmaceutical Co.,Ltd. (上海現(xiàn)代制藥股份有限公司) (600420.SH) reported a net profit of 799.7
熱評(píng):